Director, Channel and Distribution

This role is considered Virtual. Overview Reporting to the Senior Director, U.S. Channel Distribution, Alnylam seeks an experienced and focused individual to advance our partnerships with distribution and trading partners. The primary objective of this role is to ensure Alnylam patients benefit from rapid access to our products. The Director, Channel Accounts is a key stakeholder in the successful commercialization of Alnylam's portfolio of medicines. This individual executes Alnylam's strategic imperatives, manages business relationships with key stakeholders at trading partner accounts, and ensures that the patient experience is maximized with Alnylam's trading partners. In this high-impact role, collaboration with cross-functional teams is essential. The Director, Channel Accounts will work closely with Product Supply, Finance, Patient Services, Field Reimbursement, and other critical functions. This role will not only help to drive commercial success but will also support Alnylam's mission of transforming the lives of patients through innovative drug discoveries. The successful candidate must be passionate about science and deeply motivated by the quest of delivering value to patients and their families with the long-term success of the company in mind. Key Responsibilities Execute distribution operations objectives, ensuring Alnylam's products reach HCPs and patients in a timely, efficient, and appropriate manner Establish and manage strong relationships and contractual agreements with trading partners Responsible for providing input into the strategic and tactical planning for all channel activities, utilizing trading partner and market expertise Successfully launch Alnylam products and meet corporate stocking and financial objectives Collaborate with US Patient Services to ensure seamless integration of Specialty Pharmacy and Specialty Distribution partners into hub services Maximize the patient experience with Alnylam's trading partners Identify opportunities to develop appropriate partnerships with trading partners Coordinate with Payer Marketing team to oversee development of channel account deliverables Lead quarterly business reviews and other customer facing meetings to ensure that patients are receiving excellent service levels and fully benefit from Alnylam initiatives In collaboration with internal stakeholders, understand and carry out distribution policies and procedures, including but not limited to orders, returns and inventory Collaborate with Alnylam Legal and Contracting to negotiate agreements Work with Sr. Director to scale and refine the distribution strategy, as appropriate, with any future approved indication(s) and/or sites of care. Ensure compliance with all corporate policies and industry codes in collaboration with Alnylam Legal, Regulatory and Compliance Qualifications Pharmaceutical/biotech experience required 6+ years of direct involvement in distribution operations and managing trading partners Undergraduate degree required. Masters in Business Administration or Healthcare field preferred Clear understanding of buy-and-bill dynamics Product launch experience required Strategic thinking: understand account priorities and impact to key stakeholders Proven ability to effectively and skillfully negotiate, communicate and have challenging conversations with internal and external stakeholders Ability to travel up to 30% Expectations Clear Alignment with Alnylam Core Values: Commitment to People Innovation and Discovery Purposeful Urgency Open Culture Passion for Excellence Key Skills, Abilities and Competencies Distribution Channel Dynamics: Deep knowledge of US pharmaceutical channel dynamics, reimbursement environment, and strategic contracting Influence and Leadership: Influences without formal authority, able to integrate resources to achieve strategic objectives, and build/maintain strong relationships. Ability to establish close collaboration with strategic partners; able to inspire and align a diverse organization. Business Acumen: Understanding of business analytics, possession of effective communication skills, strong leadership skills and the ability to influence without authority. Work Style: Works collaboratively across expertise areas and functions; seeks to advance higher goals; highly regarded across stakeholders both at senior and junior levels; inspires trust at all levels. About Alnylam: Alnylam Pharmaceuticals (Nasdaq: ALNY) has led the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare and more prevalent diseases. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach to treating diseases at their genetic source by "interfering" with mRNA that cause or contribute to disease. Since our founding in 2002, Alnylam has led the RNAi Revolution and continues to turn scientific possibility into reality. Our culture: Our people-first culture is guided by our core values: fiercely innovative, open culture, purposeful urgency, passion for excellence, and commitment to people, and these values influence how we work and the business decisions we make. Thanks to feedback from our employees over the years, we've been fortunate to be named a top employer around the world. Alnylam is extremely proud to have been recognized as one of Science Magazine's Top Biopharma Employers, one of America's Most Responsible Companies for 2024 by Newsweek, a Fast Company Best Workplace for Innovators, and a Great Place to Work in Canada, France, Italy, Spain, Switzerland, and UK - among others. At Alnylam, we commit to an inclusive recruitment process and equal employment opportunity. We are dedicated to building an environment where employees can feel that they belong, can bring their authentic selves to work, and achieve to their full potential. By empowering employees to embrace their unique differences at work, our business grows stronger with advanced and original thinking, allowing us to bring groundbreaking medicines to patients. >

Created: 2024-11-05